Changes in T‐cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after BCMA targeted CAR T‐cell therapy in relapsed/refractory multiple myeloma: Results from a prospective comprehensive biomarker study

• DOI: 10.1111/bjh.19515
• Publication Date: 2024-05-08T23:54:23Z
• Authors: Xiang Zhou; Vivien Wagner; Lukas Scheller; Emilia Stanojkovska; Christine Riedhammer; Xianghui Xiao; Maximilian Johann...; Cornelia Vogt; Silvia Nerreter; Florian Eisele; Mara John; Umair Munawar; Sofie‐Katrin Kadel; Julia Mersi; Anna Ruckdeschel; Sven Schimanski; Larissa Haertle; Johannes Moritz W...; Seungbin Han; Max Topp; Johannes Duell; Hermann Einsele; Angela Riedel; K. Martin Kortüm; Leo Rasche
• Keywords: Cytopenia; Leukapheresis

Summary Biomarkers for cytopenias following CAR T‐cell treatment in relapsed/refractory (RR) multiple myeloma (MM) are not completely defined. We prospectively analysed 275 sequential peripheral blood (PB) samples from 58 RRMM patients treated with BCMA‐targeted T cells, and then divided them into three groups: (i) baseline (before leukapheresis), (ii) ≤day+30, (iii) >day+30 after therapy. evaluated laboratory data performed flow cytometry to determine the (CAR) subsets. Baseline hyperferritinaemia was a risk factor long‐lasting grade ≥3 anaemia ( r = 0.47, p < 0.001) thrombocytopenia 0.44, 0.002) Low haemoglobin (Hb) PLT were associated −0.56, −0.44, respectively. observed dynamics of CAR‐negative subsets infusion. In late phase therapy (>day+30), CD4Tn frequency correlated 0.41, 0.0014) lymphocytopenia related frequencies CD8 + cells 0.72, CD8Teff 0.64, 0.001). CD4Tcm leucocytopenia −0.49, summary, preexisting indicated long duration post‐CAR cytopenias. Prolonged cytopenia may be immune remodelling shift